MCID: VSC018
MIFTS: 38

Visceral Steatosis

Categories: Rare diseases, Liver diseases

Aliases & Classifications for Visceral Steatosis

MalaCards integrated aliases for Visceral Steatosis:

Name: Visceral Steatosis 49 51
Fatty Metamorphosis of Viscera 49 69
Fatal Neonatal Hepatic Steatosis 49
White Liver Disease 49
Steatosis of Liver 49
Steatohepatitis 69

Classifications:



External Ids:

Summaries for Visceral Steatosis

MalaCards based summary : Visceral Steatosis, also known as fatty metamorphosis of viscera, is related to visceral steatosis, congenital and fatty liver disease. An important gene associated with Visceral Steatosis is SLC22A5 (Solute Carrier Family 22 Member 5), and among its related pathways/superpathways are AMP-activated Protein Kinase (AMPK) Signaling and AMPK Enzyme Complex Pathway. The drugs Rosiglitazone and Ezetimibe have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and heart.

Related Diseases for Visceral Steatosis

Diseases in the Visceral Steatosis family:

Visceral Steatosis, Congenital

Diseases related to Visceral Steatosis via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 visceral steatosis, congenital 12.1
2 fatty liver disease 11.1
3 carbonic anhydrase va deficiency, hyperammonemia due to 9.9
4 blood group, i system 9.8
5 azoospermia 9.8
6 carnitine palmitoyltransferase i deficiency 9.6 CPT1A CPT1B
7 carnitine palmitoyltransferase ii deficiency, infantile 9.5 CPT1A CPT1B
8 body mass index quantitative trait locus 11 9.4 CPT1A CPT1B

Graphical network of the top 20 diseases related to Visceral Steatosis:



Diseases related to Visceral Steatosis

Symptoms & Phenotypes for Visceral Steatosis

Drugs & Therapeutics for Visceral Steatosis

Drugs for Visceral Steatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 427)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rosiglitazone Approved, Investigational Phase 4,Phase 2 122320-73-4 77999
2
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
3
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 111025-46-8 4829
4
Simvastatin Approved Phase 4 79902-63-9 54454
5
Zinc Approved, Investigational Phase 4,Phase 2 7440-66-6 32051 23994
6
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2 7439-89-6 23925
7
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 4091 14219
8
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
9
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
10
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
11
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
12
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
13
Amlodipine Approved Phase 4 88150-42-9 2162
14
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
15
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
16
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2 44147092
17
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
18
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
19
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
20
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
21
Rifampin Approved Phase 4,Phase 1 13292-46-1 5381226 5458213
22
Tamoxifen Approved Phase 4 10540-29-1 2733526
23
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
24
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
25
Gliclazide Approved Phase 4 21187-98-4 3475
26
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 657311 5754
27
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
28
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
29
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
30
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
31
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
32
Cortisone acetate Approved, Investigational Phase 4 1950-04-4, 50-04-4 5745
33
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
34
Menthol Approved Phase 4 2216-51-5 16666
35
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
36
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3 80621-81-4 6436173
37
Insulin Aspart Approved Phase 4 116094-23-6 16132418
38
Insulin Detemir Approved Phase 4 169148-63-4 5311023
39 Racepinephrine Approved Phase 4,Phase 2 329-65-7
40
Glimepiride Approved Phase 4 93479-97-1 3476
41
Empagliflozin Approved Phase 4,Phase 3 864070-44-0
42
Toremifene Approved, Investigational Phase 4 89778-26-7 3005573
43
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 5311068 56032 68602
44
Saxagliptin Approved Phase 4 361442-04-8 11243969
45
Choline Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Early Phase 1 62-49-7 305
46
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 1406-16-2
47 Tocopherol Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
48
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-14-6 5280793
49
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-02-9 14985
50
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 65-23-6 1054

Interventional clinical trials:

(show top 50) (show all 847)

# Name Status NCT ID Phase Drugs
1 Complex Imaging Assessment of Steatosis Unknown status NCT02669641 Phase 4
2 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
3 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
4 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
5 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
6 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
7 Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
8 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
9 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
10 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
11 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
12 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
13 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
14 Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
15 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed NCT01006889 Phase 4 Exenatide
16 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
17 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
18 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
19 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
20 Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
21 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
22 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
23 Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection Completed NCT01900015 Phase 4 Raltegravir;Efavirenz
24 Antidiabetic Effects on Intrahepatic Fat Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
25 The Effect of Vitamin D Supplementation in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
26 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
27 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
28 Liver Safety Under Upfront Arimidex vs Tamoxifen Completed NCT00537771 Phase 4 Anastrozole;Tamoxifen
29 The Effects of PXR Activation on Hepatic Fat Content Completed NCT02329405 Phase 4 Rifampicin;Placebo
30 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
31 Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
32 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism Completed NCT02102646 Phase 4 Triptorelin
33 Pioglitazone in Hepatitis C Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
34 Use of Metformin in Treatment of Childhood Obesity Completed NCT02274948 Phase 4 Metformin;Placebo
35 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
36 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
37 Lactate Metabolism Study in HIV Infected Persons Completed NCT00202228 Phase 4 cofactor supplementation (thiamine, riboflavin, L-carnitine)
38 Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4 sodium phenylbutyrate;Placebo
39 A Study of the Effects of Exercise Intensity on Insulin Sensitivity in Overweight Youth Completed NCT00755547 Phase 4
40 Adding Liraglutide to High Dose Insulin: Breaking the Cycle Completed NCT01505673 Phase 4 Liraglutide;Saline
41 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
42 Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. Completed NCT00107653 Phase 4 Ribavirin;Peginterferon alfa-2a;Ribavirin;Peginterferon alfa-2a
43 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Completed NCT02277587 Phase 4 Plenadren;Conventional glucocorticoid therapy
44 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Recruiting NCT02303730 Phase 4 Exenatide;insulin glargine
45 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Recruiting NCT02051842 Phase 4 Metadoxine
46 SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD Recruiting NCT02649465 Phase 4 Tofogliflozin;Glimepiride
47 Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus. Recruiting NCT03007329 Phase 4 Exenatide;Exenatide matching Placebo;Dapagliflozin
48 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Recruiting NCT02964715 Phase 4 Empagliflozin
49 Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Recruiting NCT02500147 Phase 4 Metformin;Placebo
50 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Recruiting NCT02637973 Phase 4 Empagliflozin;Placebo

Search NIH Clinical Center for Visceral Steatosis

Genetic Tests for Visceral Steatosis

Anatomical Context for Visceral Steatosis

MalaCards organs/tissues related to Visceral Steatosis:

38
Liver, Testes, Heart, Endothelial, Kidney, Bone, Brain

Publications for Visceral Steatosis

Articles related to Visceral Steatosis:

(show all 33)
# Title Authors Year
1
Failure of the feeding response to fasting in carnitine-deficient juvenile visceral steatosis (JVS) mice: involvement of defective acyl-ghrelin secretion and enhanced corticotropin-releasing factor signaling in the hypothalamus. ( 19744557 )
2009
2
Expression and distribution of OCTN2 in mouse epididymis and its association with obstructive azoospermia in juvenile visceral steatosis mice. ( 16734862 )
2006
3
Attenuation of cardiac hypertrophy in carnitine-deficient juvenile visceral steatosis (JVS) mice achieved by lowering dietary lipid. ( 16452314 )
2006
4
Identification of the up- and down-regulated genes in the heart of juvenile visceral steatosis mice. ( 15056854 )
2004
5
Functional disorders of the oxidative phosphorylation system in the heart mitochondria of mice with juvenile visceral steatosis. ( 12612434 )
2003
6
Effect of gamma-butyrobetaine on fatty liver in juvenile visceral steatosis mice. ( 11341370 )
2001
7
The signaling pathway of cardiotrophin-1 is not activated in hypertrophied ventricles of carnitine-deficient juvenile visceral steatosis (JVS) mice. ( 10904873 )
2000
8
Antagonizing effect of AP-1 on glucocorticoid induction of urea cycle enzymes: a study of hyperammonemia in carnitine-deficient, juvenile visceral steatosis mice. ( 11136545 )
2000
9
Catecholamine metabolism inhibitors and receptor blockades only partially suppress cardiac hypertrophy of juvenile visceral steatosis mice with systemic carnitine deficiency. ( 10210276 )
1999
10
Dysfunctions of the epididymis as a result of primary carnitine deficiency in juvenile visceral steatosis mice. ( 10100867 )
1999
11
Cardiomegaly in the juvenile visceral steatosis (JVS) mouse is reduced with acute elevation of heart short-chain acyl-carnitine level after L-carnitine injection. ( 10025944 )
1999
12
Loss of wild-type carrier-mediated L-carnitine transport activity in hepatocytes of juvenile visceral steatosis mice. ( 10498652 )
1999
13
Pyruvate dehydrogenase kinase 4 mRNA is increased in the hypertrophied ventricles of carnitine-deficient juvenile visceral steatosis (JVS) mice. ( 10609898 )
1999
14
Decreased tissue distribution of L-carnitine in juvenile visceral steatosis mice. ( 10087008 )
1999
15
Characteristics of cardiac hypertrophy in the juvenile visceral steatosis mouse with systemic carnitine deficiency. ( 9602426 )
1998
16
A missense mutation of mouse OCTN2, a sodium-dependent carnitine cotransporter, in the juvenile visceral steatosis mouse. ( 9837751 )
1998
17
The effect of carnitine on ketogenesis in perfused livers from juvenile visceral steatosis mice with systemic carnitine deficiency. ( 9212045 )
1997
18
Secondary abnormality of carnitine biosynthesis results from carnitine reabsorptional system defect in juvenile visceral steatosis mice. ( 9540857 )
1997
19
Suppressed expression of the urea cycle enzyme genes in the liver of carnitine-deficient juvenile visceral steatosis (JVS) mice in infancy and during starvation in adulthood. ( 9058209 )
1997
20
Abnormal gene expression causing hyperammonemia in carnitine-deficient juvenile visceral steatosis (JVS) mice. ( 9286432 )
1997
21
A novel gene suppressed in the ventricle of carnitine-deficient juvenile visceral steatosis mice. ( 9187371 )
1997
22
Altered expression of carnitine palmitoyltransferase II in liver, muscle, and heart of mouse strain with juvenile visceral steatosis. ( 8605222 )
1996
23
Increased expression of carnitine palmitoyltransferase I gene is repressed by administering L-carnitine in the hearts of carnitine-deficient juvenile visceral steatosis mice. ( 8830050 )
1996
24
Disordered expression of glycolytic and gluconeogenic liver enzymes of juvenile visceral steatosis mice with systemic carnitine deficiency. ( 8858199 )
1996
25
Carnitine transport defect in fibroblasts of juvenile visceral steatosis (JVS) mouse. ( 8670273 )
1996
26
Mapping of jvs (juvenile visceral steatosis) gene, which causes systemic carnitine deficiency in mice, on chromosome 11. ( 7626891 )
1995
27
Mitochondrial abnormalities of muscle tissue in mice with juvenile visceral steatosis associated with systemic carnitine deficiency. ( 7773507 )
1995
28
Primary defect of juvenile visceral steatosis (jvs) mouse with systemic carnitine deficiency is probably in renal carnitine transport system. ( 8155735 )
1994
29
Cardiac hypertrophy in juvenile visceral steatosis (jvs) mice with systemic carnitine deficiency. ( 8325377 )
1993
30
Abnormal expression of urea cycle enzyme genes in juvenile visceral steatosis (jvs) mice. ( 1540663 )
1992
31
Proto-oncogene c-jun and c-fos messenger RNAs increase in the liver of carnitine-deficient juvenile visceral steatosis (jvs) mice. ( 1383034 )
1992
32
Carnitine administration to juvenile visceral steatosis mice corrects the suppressed expression of urea cycle enzymes by normalizing their transcription. ( 1544887 )
1992
33
Animal model of systemic carnitine deficiency: analysis in C3H-H-2 degrees strain of mouse associated with juvenile visceral steatosis. ( 1996978 )
1991

Variations for Visceral Steatosis

Expression for Visceral Steatosis

Search GEO for disease gene expression data for Visceral Steatosis.

Pathways for Visceral Steatosis

GO Terms for Visceral Steatosis

Cellular components related to Visceral Steatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrial outer membrane GO:0005741 8.62 CPT1A CPT1B

Biological processes related to Visceral Steatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transport GO:0006810 9.5 CPT1A CPT1B SLC22A5
2 fatty acid metabolic process GO:0006631 9.26 CPT1A CPT1B
3 fatty acid beta-oxidation GO:0006635 9.16 CPT1A CPT1B
4 carnitine shuttle GO:0006853 8.96 CPT1A CPT1B
5 carnitine metabolic process GO:0009437 8.62 CPT1A SLC22A5

Molecular functions related to Visceral Steatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity, transferring acyl groups GO:0016746 8.96 CPT1A CPT1B
2 carnitine O-palmitoyltransferase activity GO:0004095 8.62 CPT1A CPT1B

Sources for Visceral Steatosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....